AWM
MYGN icon

Accel Wealth Management’s Myriad Genetics MYGN Stock Holding History

Accel Wealth Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35
Closed -$813 – 610
2023
Q1 		$813 Hold
35
– – ﹤0.01% 1191
2022
Q4 		$508 Hold
35
– – ﹤0.01% 1015
2022
Q3 		$1K Hold
35
– – ﹤0.01% 1007
2022
Q2 		$1K Buy
+35
New +$727 ﹤0.01% 967

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Accel Wealth Management's MYGN Position: Q2 2023 in Review

Accel Wealth Management sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 35 shares — an estimated $813 sold.

Accel Wealth Management first reported a position in MYGN in Q2 2022 and held it in 4 quarters. The position peaked at $1K in Q3 2022. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

  • Accel Wealth Management reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
  • Accel Wealth Management sold 35 Myriad Genetics shares in Q2 2023, an estimated $813.
  • Accel Wealth Management first reported a position in Myriad Genetics in Q2 2022 and held it in 4 quarters.
  • Accel Wealth Management's Myriad Genetics position peaked at $1K in Q3 2022.
  • 188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Accel Wealth Management's 13F filing for Q2 2023, filed 24 Jul 2023.